Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News Feature
  • Published:

Pharma deal making: a bright spot amid the gloom

Nature Biotechnology volume 41, pages 1365–1372 (2023)Cite this article

Biopharma M&A is back and IPOs are possible, but most biotechs aren’t out of the woods.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Merger and acquisition activity over time.
Fig. 2: IPO activity over time.
Fig. 3: Licensing activity over time.
Fig. 4: Licensing activity by therapeutic area.

Author information

Authors and Affiliations

  1. London, UK

    Melanie Senior

Authors
  1. Melanie Senior
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Senior, M. Pharma deal making: a bright spot amid the gloom. Nat Biotechnol 41, 1365–1372 (2023). https://doi.org/10.1038/s41587-023-01958-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-023-01958-7

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing